DISCLAIMER: The views and opinions expressed in this column are solely those of the author and do not necessarily reflect the official policy or position of ...
6d
Bulimba bar gets green light after brothers dial back grand plans for four-storey commercial space
A pair of entrepreneurial brothers who lost their bid to build a hotel in a massive four-storey commercial building next to ...
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...
In March 2014, Anaptys entered into the Collaboration Agreement with Tesaro, an oncology-focused biopharmaceutical company now a part of GSK. Currently, under the Collaboration Agreement, Tesaro is ...
Retail investors are showing signs of waning confidence in the U.S. stock market's ability to rebound, with market data and analysts' observations both indicating an ebb in their enthusiasm about ...
WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025, after the ...
The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team’s exclusive jersey patch partner. This landmark ...
Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...
WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration ...
Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback